Post-ERCP Acute Pancreatitis
44
4
4
24
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.8%
3 terminated out of 44 trials
88.9%
+2.3% vs benchmark
20%
9 trials in Phase 3/4
33%
8 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 24 completed trials
Clinical Trials (44)
Papillary Epinephrine Injection vs Rectal Indomethacin
Indomethacin for Biliary ERCP Patients
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
Rectal Indomethacin vs Intravenous Ketorolac
Low-acid Contrast Media for Preventing Post ERCP Pancreatitis
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
Rectal NSAIDs With/Without PD Stent for PEP Prevention
Study of Forceps Cannulation During ERCP
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
ESGE-Quality Improvement in Endoscopy: ERCP
Optimal Placement Duration of Pancreatic Duct Stent
Prevention of Post-ERCP Pancreatitis by Indomethacin Vs Diclofenac
Statins and Post-ERCP Acute Pancreatitis (Stark Project)
Prediction of PEP Based on the Appearance of the Major Duodenal Papilla
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis